Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib + Trastuzumab in Metastatic Breast Cancer
NCT00243503Phase 2Completed
- Sponsor
- Pfizer
- Start
- Feb 2006
- Primary completion
- Apr 2009
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in breast cancer, sponsored by Pfizer. Primary endpoint: Overall Confirmed Objective Disease Response at 18 months. Started Feb 2006; status: completed.
02
Drugs
sunitinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00243503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00243503.